NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer

Gynecologic Oncology

Volumn 145, Issue 3, 2017, Pages 420-425

  Szender, J Brian ^a   Papanicolau Sengos, Antonios ^b   Eng, Kevin H ^a   Miliotto, Anthony J ^a   Lugade, Amit A ^a   Gnjatic, Sacha ^c   Matsuzaki, Junko ^a   Morrison, Carl D ^b   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Omniseq LLC   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DECITABINE; NY ESO 1 ANTIGEN; CTAG1B PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; ADOLESCENT; BIOSYNTHESIS; CANCER GRADING; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; OVARIAN NEOPLASMS; PHENOTYPE; YOUNG ADULT;

EID: 85017189861     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.03.509     Document Type: Article

References (29)

1. Alberts, D.S., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335:26 (1996), 1950–1955.
2. Armstrong, D.K., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354:1 (2006), 34–43.
3. Markman, M., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19:4 (2001), 1001–1007.
4. McGuire, W.P., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1 (1996), 1–6.
5. Ozols, R.F., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21:17 (2003), 3194–3200.
6. Burger, R.A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365:26 (2011), 2473–2483.
7. Pignata, S., et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 16:5 (2015), 561–568.
8. Almeida, L.G., et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 37:Database issue (2009), D816–D819.
9. Chen, Y.T., et al. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 91:3 (1994), 1004–1008.
10. Odunsi, K., et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc. Natl. Acad. Sci. U. S. A. 109:15 (2012), 5797–5802.
11. Odunsi, K., et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 63:18 (2003), 6076–6083.
12. Jungbluth, A.A., et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int. J. Cancer 92:6 (2001), 856–860.
13. Gnjatic, S., Old, L.J., Chen, Y.T., Autoantibodies against cancer antigens. Methods Mol. Biol. 520 (2009), 11–19.
14. Odunsi, K., et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol. Res. 2:1 (2014), 37–49.
15. Odunsi, K., et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 104:31 (2007), 12837–12842.
16. Berinstein, N.L., et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J. Transl. Med., 10, 2012, 156.
17. Nishikawa, H., et al. Influence of CD4 + CD25 + regulatory T cells on low/high-avidity CD4 + T cells following peptide vaccination. J. Immunol. 176:10 (2006), 6340–6346.
18. Tsuji, T., et al. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8 + and CD4 + T cell responses with broad antigen specificity. J. Immunol. 186:2 (2011), 1218–1227.
19. Hamanishi, J., et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33:34 (2015), 4015–4022.
20. Hodi, F.S., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 100:8 (2003), 4712–4717.
21. Mashino, K., et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br. J. Cancer 85:5 (2001), 713–720.
22. Jager, E., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187:2 (1998), 265–270.
23. Kurashige, T., et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 61:12 (2001), 4671–4674.
24. Rizvi, N.A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:6230 (2015), 124–128.
25. Gaillard, S.L., Secord, A.A., Monk, B., The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol. Oncol. Res. Pract., 3, 2016, 11.
26. Koebel, C.M., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:7171 (2007), 903–907.
27. Webb, J.R., et al. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol. 141:2 (2016), 293–302.
28. Martin, S.D., et al. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS One, 11(5), 2016, e0155189.
29. Dong, Z.Y., et al. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumour Biol. 37:4 (2016), 4251–4261.